NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA

Inventors: Michael A. Apicella, Solon, IA (US); Melvin G. Sunshine, Iowa City, IA (US); Na-Gyong Lee, Incheon (KR); Bradford W. Gibson, Berkeley, CA (US)

Assignees: University of Iowa Research Foundation, Iowa City, IA (US); The Regents of the University of California, Oakland, CA (US)

* Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 60 days.

This patent is subject to a terminal disclaimer.

(11) Appl. No.: 11/087,235
(22) Filed: Mar. 23, 2005

Prior Publication

Related U.S. Application
Division of application No. 08/565,943, filed on Dec. 1, 1995, now Pat. No. 6,887,483.

Int. CI.
A01N 63/00 (2006.01)
A61K 39/02 (2006.01)
A61K 39/102 (2006.01)
A61K 39/116 (2006.01)
C12N 15/09 (2006.01)
C12P 29/06 (2006.01)
C12P 19/04 (2006.01)

U.S. CL. ............... 424/93.2, 424/93.4, 424/200.1, 424/256.1; 424/234.1; 424/184.1; 424/203.1; 435/69.3; 435/69.1; 435/71.1; 536/123.1

Field of Classification Search ............ 424/93.4, 424/93.48, 200.1, 184.1, 234.1, 256.1, 286.1, 424/257.1, 249.1, 203.1; 435/71.1, 69.3, 435/69.1; 536/123.1; 426/93.2

See application file for complete search history.

References Cited
U.S. PATENT DOCUMENTS
4,929,694 A 5/1990 Munford et al.
5,200,184 A 4/1993 Munford et al.
5,631,010 A 5/1997 Mekalanos ............... 424/235.1
6,482,807 B1 11/2002 Van Der Ley et al.
6,548,287 B1 4/2003 Powell et al.
6,887,483 B2 5/2005 Apicella et al.

FOREIGN PATENT DOCUMENTS
EP 0 306 496 11/1995
WO WO 87/07297 12/1987
WO WO 97/18837 5/1997
WO WO 97/19688 6/1997

OTHER PUBLICATIONS

(Continued)

Primary Examiner—S. Devi
Attorney, Agent, or Firm—Vietnins Harris & Pady P.L.L.P

ABSTRACT
A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional HtrB protein, resulting in a mutant that lacks one or more secondary acyl chains and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, or the endotoxin isolated therefrom, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

4 Claims, 3 Drawing Sheets
OTHER PUBLICATIONS


Zähringer et al., “Molecular structure of lipid A, the endotoxic center of bacterial lipopolysaccharides”, Advances in Carbohydrate Chemistry and Biochemistry, 50, 211-276 (1994).

* cited by examiner
NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA

This application is a divisional of and claims the benefit of priority under 35 U.S.C. § 120 to U.S. application Ser. No. 08/565,943, having a filing date of Dec. 1, 1995, which issued as U.S. Pat. No. 5,887,483. The disclosure of the prior application is incorporated by reference in its entirety.

This invention has been made with government support under grant AI 24616 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to compositions comprising altered endotoxin (lipooligosaccharide (LOS); lipopolysaccharide (LPS)) of gram-negative bacterial pathogens. More particularly, the present invention relates to the making of a form of endotoxin, by a genetically engineered gram-negative pathogen, which lacks a substantially toxic lipid A portion. Also disclosed are prophylactic and therapeutic uses of the substantially detoxified endotoxin, and of mutant gram-negative bacteria producing the substantially detoxified endotoxin.

BACKGROUND OF THE INVENTION

Gram-negative bacteria have an outer membrane comprised of components including proteins, lipoproteins, phospholipids, and glycolipids. The glycolipids comprise primarily endotoxin-lipopolysaccharides (LPS) or lipooligosaccharides (LOS), depending on the genus of bacteria. LPS are molecules comprised of:

a) a lipid A portion which consists of a glucosamine disaccharide that is substituted with phosphate groups and long chain fatty acids in ester and amide linkages;

b) a core polysaccharide which is attached to lipid A by an eight carbon sugar, KDO (ketodeoxyoctonate), and heptose, glucosyl, galactose, and N-acetylgalactosamine; and

c) an O-specific side chain comprised of repeating oligosaccharide units which, depending on the genera and species of bacteria, may contain mannose, galactose, D-glucose, N-acetylgalactosamine, N-acetylgalactosamine, L-rhamnose, and a disaccharide hexose (abequose, colitose, tyvelose, paratose, trehalose). LOS has a similar structure as LPS, containing a lipid A portion and a complex carbohydrate structure, but differs in that it does not contain repeating O-side chains.

The major antigenic determinants of gram-negative bacteria are believed to reside in the carbohydrate structure of the O-specific side chain of LPS and the complex carbohydrate structure of LOS. These carbohydrate structures may vary for different species of the same genera of gram-negative bacteria by varying one or more of the sugar composition; the sequence of oligosaccharides; the linkage between the oligosaccharides; and substitutions/modifications of an oligosaccharide (particularly a terminal oligosaccharide).

LPS and LOS have been considered as bacterial components which have potential as vaccine immunogens because of the antigenic determinants ("epitopes") residing in their carbohydrate structures. However, the chemical nature of LPS and LOS prevent the use of these molecules in vaccine formulations; i.e., active immunization with LPS or LOS is unacceptable due to the inherent toxicity of the lipid A portion. The pathophysiologic effects induced (directly or indirectly) by lipid A of LPS or LOS in the bloodstream include fever; leucopenia; leucocytosis; the Schwartman reaction; disseminated intravascular coagulation; abortion; and in larger doses, shock and death. Accordingly, there are no currently available vaccines which induce antibody responses to LPS or LOS epitopes.

As shown in FIG. 1, the lipid A portion of endotoxin generally comprises a hydrophilic backbone of glucosamine disaccharide which is either monophosphorylated or diphosphorylated (positions 1 and 4); and which carries at least six molecules of ester- and amide-bound fatty acids. Four molecules of (R)-3-hydroxytetradecanoate (e.g., 3-hydroxy-myristoyl or β-hydroxybutyric acid or β-OH) are linked directly to the lipid A backbone at positions 2, 3, 2', and 3'. Hydroxyl groups of two of the four molecules of β-OH are substituted with normal fatty acids (termed "secondary acyl chains", and including dodecanoate, tetradecanoate, and hexadecanoate) in forming acyloxyacyl groups.

One approach to making a detoxified endotoxin molecule involves isolating the endotoxin, and enzymatically treating the isolated endotoxin with a human stomach enzyme acyloxyacyl-hydroxylase (U.S. Pat. Nos. 4,929,604, 5,013,661 and 5,200,184). The acyloxyacyl hydroxylase hydrolyzes the fatty acids (non-hydroxylated, secondary acyl chains) from their ester linkages to hydroxy groups of β-OH (hydroxylated). The resultant altered endotoxin, from enzymatic treatment, contained a lipid A moiety lacking non-hydroxylated fatty acids. This altered endotoxin exhibited reduced in vivo toxicity, but retained antigenicity.

Another approach involves a method of modifying isolated endotoxin by selectively removing the β-OH that is ester-linked to the reducing-end glucosamine backbone at position 3 (U.S. Pat. No. 4,912,094; Reexamination U.S. Pat. No. B1 4,912,094). The selective removal of β-OH was accomplished using alkaline hydrolysis. The resultant modified endotoxin exhibited reduced in vivo toxicity, but retained antigenicity.

Both approaches involve chemically treating isolated endotoxin. Neither approach discloses the production in a gram negative bacterial pathogen of an endotoxin having substantially reduced toxicity, yet retaining antigenicity. Further, there has been no disclosure of the use of a gram-negative bacteria, which has been engineered to produce an endotoxin having substantially reduced toxicity and yet retaining antigenicity, in a prophylactic or therapeutic vaccine against endotoxic shock and gram-negative bacteria.

SUMMARY OF THE INVENTION

The present invention is directed to a method for producing, in a mutant gram-negative pathogen, LPS or LOS which exhibits substantially reduced toxicity as compared to the wild type endotoxin, and which retains the antigenicity of its corresponding wild type endotoxin. The method comprises creating a mutation in the htrB gene of the gram-negative bacterial pathogen such that there is a lack of functional HrB protein in the mutated gram-negative bacterial pathogen. It was found that lipid A produced by the htrB mutant lacks one or both of the fatty acids (non-hydroxylated or secondary acyl chains) thereby rendering the endotoxin in an isolated form, or the mutant gram-negative bacterial pathogen bearing the endotoxin, substantially reduced in toxicity and yet retaining antigenicity, as compared to wild type.

Endotoxin isolated from htrB mutants, or the htrB mutants themselves (whole cell vaccine), can be used to immunize individuals at risk of gram-negative bacteremia by inducing
antibodies to the major antigenic determinants which reside in the carbohydrate structure of the O-specific side chain of LPS and the complex carbohydrate structure of LOS. Further, the \textit{htrB} mutants can be engineered to express heterologous antigens of other microbial pathogens at the surface of the \textit{htrB} mutant for presentation to a vaccinated individual's immune system in a multivalent vaccine. Also, the endotoxin isolated from the \textit{htrB} mutants of the present invention may be used to generate LPS or LOS-specific antibody which may be useful for passive immunization and as reagents for diagnostic assays directed to detecting the presence of gram-negative bacterial pathogens in clinical specimens.

**BRIEF DESCRIPTION OF THE FIGURES**

**FIG. 1** is a schematic representation of the general structure of lipid A of gram negative bacteria of the family Enterobacteriaceae.

**FIG. 2A** is a schematic representation of the general structure of a species of lipid A, from the LOS of an \textit{htrB} mutant, comprising pentaacetyl diphosphoryl lipid A.

**FIG. 2B** is a schematic representation of the general structure of a species of lipid A, from the LOS of an \textit{htrB} mutant, comprising tetraacetyl diphosphoryl lipid A.

**FIG. 3** is a graph showing the relative toxicity of an \textit{htrB} mutant (○, ○); as compared to wild type bacteria (□) in a TNF-α release assay.

**DETAILED DESCRIPTION OF THE INVENTION**

Definitions:

“Endotoxin” is a term used herein for purposes of the specification and claims to refer to the LPS of the LOS of gram-negative bacterial pathogens, wherein the endotoxin is either in a cell-associated or isolated form. “\textit{htrB} endotoxin” refers to endotoxin isolated and purified from a gram-negative bacterial pathogen \textit{htrB} mutant”.

“vaccine candidate or vaccine antigen” is a term used herein for purposes of the specification and claims to refer to an antigen having one or more of the following properties (a-d): (a) is immunogenic; (b) is surface-exposed (which can be shown by techniques known in the art including immunofluorescence assays, electron microscopy staining procedures, and by bactericidal assays); (c) induces antibody having bactericidal activity in the presence of complement and/or functions in immune clearance mechanisms; (d) induces antibody which neutralizes other functional activity of the epitope (immunogenicity, or toxicity, etc.).

“Gram-negative bacterial-pathogen” is a term used herein for purposes of the specification and claims to refer to one or more pathogenic (to humans or animals) bacterium of a genus and species including \textit{Neisseria meningitidis}, \textit{Neisseria gonorrhoeae}, \textit{Haemophilus influenzae}, \textit{Haemophilus ducreyi}, other \textit{Haemophilus} species, \textit{Moraxella catarrhalis}, \textit{Campylobacter jejuni}, \textit{Salmonella typhimurium}, other \textit{Salmonella} species, \textit{Shigella dysenteriae}, and other \textit{Shigella} species, and \textit{Pseudomonas aeruginosa}.

“Substantially reduced in toxicity” is a term used herein for purposes of the specification and claims to refer to a reduction in bioactivity of at least 10 fold to 100 fold as compared to wild type endotoxin.

The methods and compositions of the present invention relate to LPS and LOS biosynthetic pathways of gram-negative bacterial pathogens. More specifically, the present invention relates to mutations in the \textit{htrB} gene of gram-negative bacterial pathogens resulting in mutant bacteria bearing endotoxin which is substantially reduced in toxicity, and yet retains antigenicity, as compared to wild type bacteria of the same species.

The genetics of lipid A biosynthesis of enteric bacteria, as it was known at the time of the present invention, is summarized in Schnaitman and Klena (1993, Microbiol. Rev. 57:655–682). Genes \textit{lpxA}, \textit{lpxB}, \textit{lpxC}, and \textit{lpxD} encode gene products which function on the glucosamine backbone of lipid A including transfer of β-hydroxyacyl to glucosamine. The \textit{htrB} gene was described as a gene that affects the inner core structure (KDO, heptose, phosphoethanolamine (PEA)) which was discovered during a screen for genes necessary for growth of \textit{Escherichia coli} at elevated temperatures. Knockout mutations of \textit{htrB} resulted in mutant \textit{E. coli} which exhibited a reduced sensitivity to deoxycholate, an inability to grow at temperatures above 32.5°C, and a decrease in LPS staining intensity (Schnaitman et al., 1993, supra; Karow et al., 1992. J. Bacteriol. 174:7407–7418). Karow et al. further noted that at between about 30°C to about 42°C, \textit{E. coli} \textit{htrB} mutants have changes in the fatty acid composition of both LPS and phospholipids, and particularly, overproduce phospholipids, as compared to wild type. However, it was neither known nor suggested which one or more of the at least six molecules of ester- or amide bound fatty acids is lacking in the lipid A portion of LPS of \textit{htrB} mutants. Also no mention was made that \textit{htrB} mutants contained a lipid A moiety specifically lacking one or both non-hydroxylated (secondary acyl) chain fatty acids responsible for endotoxicity; i.e. that the \textit{htrB} mutant contained an altered endotoxin exhibiting reduced in vivo toxicity, but retaining antigenicity (“\textit{htrB} endotoxin”), as compared to wild type.

The discoveries comprising the present invention include the unexpected results that knockout mutations of the \textit{htrB} gene of gram-negative bacteria (including the family Enterobacteriaceae) result in \textit{htrB} mutants which specifically lack one or more secondary acyl chain fatty acids which are ester-bound to the hydroxyl groups of two of the four molecules of β-OH (as shown in FIG. 2). Thus, it appears that the \textit{HtrB} protein has either acyltransferase activity, or indirectly or directly affects regulation of acyltransferase activity. The following examples are presented to illustrate preferred embodiments of aspects of the present invention, and are not intended to limit the scope of the invention. In particular, a preferred embodiment is the making of an \textit{H. influenzae} \textit{htrB} mutant, and methods of using the same as a whole cell, or to isolate, the endotoxin, in vaccine preparations or to generate antibodies for therapeutic or diagnostic applications. However, since the lipid A moiety is highly conserved among bacteria of the family Enterobacteriaceae and closely related gram-negative bacteria, the invention relates to gram-negative bacterial pathogens, as defined previously herein. There is microheterogeneity in terms of the length of the secondary acyl chain (12 or 14 carbon chains) and to which of the four β-OH are substituted (1, 2, or 4) (Erwin et al., 1991, Infect Immun 59:1881–1887); however, the nature of the substitution is the same and thus the particular steps (genes and gene products) involved in the biosynthetic pathway appear conserved. For example, removal of secondary acyl chains from various gram-negative bacterial pathogens (\textit{E. coli}, \textit{H. influenzae}, \textit{P. aeruginosa}, \textit{S. typhimurium}, and \textit{N. meningitidis}) using human acetylhydrolase resulted in decylated LPS from all
species tested having significantly reduced mitogenic activity (Erwin et al., 1991, supra) as compared to the respective wild type strain.

EXAMPLE 1

Identification of an htrB Gene, and Generation of htrB Mutants

By complementing a nontypeable H. influenzae strain 2019 with a S. typhimurium rfaE mutant strain, the rfaE gene of H. influenzae strain 2019 was cloned (Lee et al., 1995, Infect Immun 63:818-824). Sequence analysis of the upstream region of the H. influenzae rfaE gene revealed an open reading frame highly homologous to the E. coli htrB gene. The H. influenzae htrB gene comprises 933 bases and encodes a protein, HtrB, of 311 amino acids (SEQ ID NO:1) and an estimated molecular size of 36 kilodaltons (kDa). Comparison of the deduced amino acid sequence of the H. influenzae htrB with the E. coli htrB revealed shared homology (56% identity and 73% similarity). Cloning the htrB gene of H. influenzae into a plasmid, and subsequent in vitro transcription-translation analysis, revealed that HtrB has an apparent molecular size of 32-33 kDa.

There are various standard techniques known to those skilled in the art for mutating a bacterial gene. Those techniques include site-directed mutagenesis, and shuttle mutagenesis using transposons. In one aspect of this embodiment, mutagenesis of the htrB gene was carried out by shuttle mutagenesis. A derivative of the bacterial transposon Tn3, mini-Tn3 (Seifert et al., 1986, Proc Natl Acad Sci USA 83:735--739), was used as an insertion sequence to mutate the htrB gene. A 2.4 kilobase (kb) BglII containing the htrB gene from H. influenzae was cloned into a plasmid which was used as a target for mini-Tn3 transposon mutagenesis. Briefly, introduced into a single bacterial cell (E. coli), is the plasmid containing the htrB gene; a plasmid immune to Tn3 transposition and containing transposase (which mediates the coinsertion between Tn3 and the target molecules); and a plasmid containing mini-Tn3. After allowing for transposition, the bacterial cells are mated with an E. coli strain containing the cre enzyme that is used to resolve coinserts in shuttle mutagenesis. Transconjugates were selected for with antibiotics (kanamycin, ampicillin, and streptomycin) and analyzed by restriction endonuclease digestion.

Two plasmids, termed pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location. Each plasmid was used to transform nontypeable H. influenzae strain 2019 and bacterial cell transformants were selected for by growth in the presence of chloramphenicol (1.5 μg/ml) resulting in identification of mutant strains designated NTHI B28 and B29, respectively. Nontypeable Haemophilus influenzae strains 2019 B28 and 2019 B29 were deposited on Nov. 14, 2000 with the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209 under the provisions of the Budapest Treaty, and all restrictions will be irrevocably removed upon the granting of a patent on this application. Strain B28 has been accession number PTA-2667 and strain B29 has been accession number PTA-2668. Locations of the miniTn insertion in the chromosomes of the NTHI mutants were confirmed by genomic Southern hybridization using the 2.4 kb BglII fragment as a probe. In particular, a BglII digest of NTHI strain 2019 DNA resulted in a 2.4 kb fragment; whereas similar digests of DNA from mutants NTHI B28 and B29 revealed 4.0 kb fragments. Further, the 4.0 kb fragments were digested by EcoRI which is present in the miniTn3.

Alternatively, methods are known in the art to perform site-directed mutagenesis into a bacterial gene (See for example, Halladay, 1993, J. Bacteriol. 175:684-692), and recombination of the mutated bacterial gene into the bacterial chromosome. A selectable kanamycin resistance cassette may be used to insert into, and mutate, the htrB gene contained within a shuttle plasmid. Subsequent transformation into a bacterial host cell with the shuttle plasmid, and recombination of the bacterial genome (at the site of the genomic copy of the htrB gene) with the cassette via htrB flanking sequences, results in the site-directed mutagenesis of the bacterial htrB gene.

Primer extension analysis can be used to determine the promoter region of the htrB gene. The H. influenzae htrB’s promoter region was determined by primer extension analysis by first growing the bacteria, harvesting and purifying the RNA, and using a commercial primer extension kit according to the manufacturer’s suggestions. A single transcription site was found using a primer (SEQ ID NO:2) complementary to the 5’ region of the htrB open reading frame. The first nucleotide was a cytosine (C) residue located at 21 bp upstream of the putative translation start site, ATG. The region upstream of the transcription start site contained a sequence (SEQ ID NO:1, bases 13 to 29) similar to the consensus -10 region of the bacterial c77-dependent promoters at an appropriate distance. An element (SEQ ID NO:1, bases 1 to 6) resembles the consensus sequence of the -35 region.

EXAMPLE 2

Characterization of htrB Mutants

Growth Characteristics

NTHI B28 and B29 strains were initially selected at 30° C., and were unable to grow at 37° C. With further passages at 30° C., the NTHI htrB mutants began to lose temperature sensitivity and demonstrated a slow rate of growth, as compared to NTHI 2019, at 37° C. However, for growth temperatures greater than or equal to 38.5° C., the temperature sensitivity remained for the htrB mutants.

It was reported previously that E. coli htrB mutants demonstrated a change in membrane permeability to various compounds including kanamycin and deoxycholate (Kurov et al., 1992, supra). The NTHI htrB mutants were also tested for sensitivity to kanamycin and deoxycholate. Overnight cultures grown at 30° C. were then diluted and allowed to grow in the presence of 5 μg/ml kanamycin at either 30° C. or 37° C. At 30° C., no difference was detected in the growth rate between NTHI 2019 and the NTHI htrB mutant strains in the absence of kanamycin. However, the growth of the htrB mutants was significantly inhibited in the presence of kanamycin, whereas NTHI 2019 was not affected. For the htrB mutants, the sensitivity to kanamycin was even greater at 37° C., since the mutants failed to show growth in the presence of kanamycin at 37° C. Likewise, at 30° C., the htrB mutants showed sensitivity, as compared to NTHI strain 2019, at concentrations of greater than 500 μg/ml deoxycholate, and failed to grow at 1000 μg/ml. At 37° C., the htrB mutants showed almost complete inhibition of growth in the presence of only 250 μg/ml deoxycholate.
Endotoxin Characteristics

The LPS of E. coli htrB mutants has been characterized as being weakly stained on silver-stained polyacrylamide gels, but its migration pattern did not vary as compared to LPS from wild type. In contrast, the LOS from NTHi mutants B28 and B29 migrated faster than that from NTHi strain 2019 on silver-stained gels. Additionally, the LOS from the mutants displayed a brownish color rather than black, as displayed by NTHi 2019. Reconstitution, by introducing a plasmid with an intact htrB gene into the mutant, of NTHi mutant B29 confirmed that the differences in growth characteristics and LOS migration and staining were due to mutation of the htrB gene.

The htrB mutant LOS and wild type LOS were each analyzed by electrospray ionization-mass spectrometry (ESI-MS) to provide molecular mass profiles for the different components of LOS. First, LOS was isolated from the respective strains. LPS or LOS can be isolated by the phenol-water method (Westphal et al., 1965, Methods in Carbohydrate Chemistry 5:83-91) or using an alternative purification procedure using a protease; Hitchcock et al., 1983, J. Bacteriol. 154:269–277). The isolated LOS species were then O-deacylated by mild hydrazine treatment (37°C for 20 minutes; see Phillips et al., 1990, Biochem. Biophys. Mass Spectrom. 19:731–745). Analysis by ESI-MS of the different LOS species showed that while the O-deacylated LOS from NTHi mutant B29 and NTHI 2019 were similar in molecular mass profile, two differences can be clearly discerned. In the htrB mutant, there is a decrease (50% reduction) in the amount of LOS containing two phosphoethanolamines (PEA) in the inner core structure; and there is a shift to high molecular weight LOS species containing more hexoses. These findings suggest that the degree of phosphorylation may be affecting chain progression from specific heptose moieties, and that HtrB either directly or indirectly affects phosphorylation of LOS.

Mass spectrometry was used to analyze the lipid A. More specifically, lipid A from htrB mutant LOS and from wild type LOS were each analyzed by liquid secondary ion mass spectrometry (LSIMS) in the negative ion mode to provide a spectrum of molecular ions for the different components of lipid A. First, the LOS species were each hydrolyzed in 1% acetic acid for 2 hours at 100°C. At a concentration of 2 mg/ml. The hydrolysates were centrifuged, and the supernatants removed. The water soluble crude lipid A fractions were washed twice in water, and once in an organic mixture (chloroform/methanol/water; by volume 2:1:1) and then evaporated to dryness. For analysis, the lipid samples were redisolved in CH3CN/CH3OH (3:1, v/v) and 1 μl of nitrobenzylchloroform/triethanolamine (1:1, v/v) and applied as a liquid matrix onto a mass spectrometer. LSIMS of the wild type (NTHI 2019) revealed a spectrum containing two deprotonated molecular ions consistent with a hexaacyl lipid A structure containing either one (hexacyl monophosphoryl lipid A, M+ = 1744) or two phosphates (hexaacyl diphosphoryl lipid A, M+ = 1824). This spectrum is essentially identical to that reported for the lipid A structure of LOS of H. ducreyi (Melaugh et al., 1992, J. Biol. Chem. 267:13434–13439).

The lower mass fragments are believed to be ions which arise through LSIMS-induced fragmentation of higher mass mono- and diphosphorylated molecular ion species.

In contrast, the LSIMS spectrum for the lipid A preparation from the htrB mutant LOS lacks molecular ions corresponding to the wild type hexaacyl lipid A species. There are two high mass ions which correspond to the molecular ions for a mono- and diphosphoryl pentacyl lipid A species missing one of the secondary acyl chains (e.g. myristic acid moiety). Further, at the lower masses are two additional molecular ion species that correspond to a mono- and diphosphoryl tetraacyl lipid A species lacking both secondary acyl chains. In summary, the lipid A structure of the wild type’s LOS is hexaacyl; whereas the lipid A structure of the htrB mutant shows two species, a tetraacyl (FIG. 2A) and a pentaacyl species (FIG. 2B) indicating the loss of at least one, and sometimes both secondary acyl chains.

EXAMPLE 3

Substantially Reduced Toxicity of htrB Mutants

The effect due to the lack of one or more secondary acyl chains on the toxicity of a gram-negative bacterial pathogen was examined using a standard in vitro assay for measuring in vivo toxicity. Murine macrophage-like cell line J774, when stimulated by LPS, secretes TNFα. The amount of TNFα, a directly proportional to the toxicity of the stimulating LPS, can be measured by (a) removing the cell-free supernatant containing the TNFα; (b) adding the supernatant to a TNFα-sensitive cell line, such as WEHI 164; and (c) measuring the resultant cytotoxicity (See for example, Espevik et al., 1986, J Immunol Methods 95:99; Sakurai et al., 1985, Cancer Immunol Immunother 20:6–10; Adams et al., 1990, J Clin Microbiol 28:998–1001; Adams et al., 1990, J Leukoc Biol 48:549–56; Tsai et al., 1992, Cell Immunol 144:203–16; and Pfister et al., 1992, Immunol 77:473–6).

In this assay, adherent J774 cells were removed from culture, washed with PBS-1 mM EDTA, and then washed twice with complete tissue culture medium without antibiotics. 2x10^6 to 4x10^6 J774 cells/100 mm culture dish were incubated in tissue culture medium overnight in a CO2 incubator. Adherent J774 cells are removed with PBS-1 mM EDTA, washed three times in tissue culture medium, and adjusted to 5x10^5/ml. Aliquots of 50 μl were added per well of a round bottom 96 well plate. The plate is then incubated or 1 hour at 37°C in a CO2 incubator. Per well is added either an htrB mutant, or the wild type strain, in various colony forming units (cfu, infection dose). The plate is then incubated at 37°C for 1 hour in a CO2 incubator. After the incubation, 100 μl of culture medium containing 50 μg/ml gentamicin is added per well. The plate is then incubated overnight at 37°C in a CO2 incubator. Aliquots of 50 μl of the J774 supernatant were removed per well and transferred into wells of a flat bottom 96 well plate. Serial 10 fold dilutions were made of the J774 supernatant. Included as a control is a dilution series of recombinant TNFα (rTNFα). Added per well is 50 μl of WEHI 164 clone 13 cells at 6x10^3 cells/ml in tissue culture medium +25 mM LiCl+2 μg/ml actinomycin D; and the mixture was incubated overnight at 37°C in a CO2 incubator. After the incubation, 10 μl of alamar blue is added, and 5–7 hours later the optical density is read at 570 nm. The assay utilizes alamar blue as a color indicator; i.e., alamar blue is converted to a red color by living cells, but remains blue if the cells are killed.

FIG. 3 shows a comparison between the number of bacterial cells of H. influenzae strain 2019 (wild type, □), and of bacterial cells of htrB mutant NTHi B29 (□ and △) necessary to stimulate the release of enough TNFα from J774 cells to kill the TNFα-susceptible cell line WEHI 164. B29_w (△) and B29_wO (□) refer to a high number and low number of passages of htrB mutant, respectively. As shown in FIG. 3, the htrB mutant shows a reduced ability to stimulate TNFα release; i.e., between an approximately 10 fold reduction (B29_wO) to an approximately 100 fold reduction (B29_w). This reduced ability to stimulate TNFα is one
indication of the htrB mutant being substantially reduced in toxicity due to the lack of one or more secondary acyl chains in the lipid A portion of the endotoxin.

The substantial reduction in toxicity exhibited by the htrB mutant, as observed by the TNFβ release assay, due to the lack of one or more secondary acyl chains is further supported by previously reported assays of biacidity of endotoxin treated with acyoxacyl hydrolase which selectively removes the secondary acyl chains from endotoxin. Decayed endotoxin from E. coli, H. influenzae, N. meningitis, and S. typhimurium were (a) similarly reduced in potency in the Limulus lysate test relative to the respective wild type endotoxin; (b) reduced in the ability to stimulate neutrophil adherence to human endothelial cells relative to the respective wild type endotoxin; and (c) reduced in mitogenic activity for murine splenocytes (Erwin et al., 1991, Infect Immun 59:1881–1887); yet maintained expression of antigenic epitopes. Similarly, S. typhimurium LPS treated with acyoxacyl hydrolase showed a reduction in toxicity by 100-fold or greater in a dermal Shwartzman reaction; was less pyrogenic in a thermal response model; showed a 5 to 12 fold reduction in B-cell mitogenicity; and showed a 10 to 20 fold reduction in the release of prostaglandin E2, as compared to wild type endotoxin, in concluding that maximally decayed LPS was at least 10 fold less toxic than wild type endotoxin (U.S. Pat. No. 4,929,604).

EXAMPLE 4

Use of htrB Mutants as Immunogens

In one aspect of this embodiment, the htrB mutant is used as a whole cell vaccine. The benefit of using live, attenuated (weakened in its ability to cause pathogenesis) bacteria as an immunogen in a vaccine formula is that they are able to survive and may persist in the human or animal body, and thus confer prolonged immunity against disease. In conjunction with the benefit of using a live bacteria to prolong the immune response, gram-negative bacterial pathogens which are htrB mutants have the added benefit in that they exhibit substantially reduced toxicity. Another advantage, as compared to a vaccine formulation comprising an isolated peptide representing a bacterial antigen, is that a bacterial antigen expressed on the surface of a bacterial cell will often result in greater stimulation of the immune response. This is because the surface of bacteria of the family Enterobacte-

riaeae acts as a natural adjuvant to enhance the immune response to an antigen presented thereon (Weizler, 1994, Ann NY Acad Sci 730:367–370). Thus, using a live bacterial vaccine, such as an htrB mutant, to express complete proteins in an native conformation (i.e., as part of the bacterial outer membrane) is likely to elicit more of a protective immune response than an isolated protein alone.

Live bacterial vaccine vectors of the family Enterobacter-
riaeae that have been described previously include attenuated Salmonella strains (Stocker et al., U.S. Pat. Nos. 5,210,035; 4,837,151; and 4,735,801; and Curtiss et al., 1988, Vaccine 6:155–160; herein incorporated by reference), and Shigella flexneri (Sizemore et al., 1995, Science 270:299–302; herein incorporated by reference). One preferred embodiment is to provide a vaccine delivery system for human or animal (depending on the genus and species of the gram-negative bacterial pathogen) mucosal pathogens. Thus, immunization by the parental route or by the mucosal route with a prophylactically effective amount of the htrB mutant, or an htrB mutant transformed to recombantly express additional bacterial antigens (that do not negatively affect the growth or replication of the transformed htrB mutant), can lead to colonization of mucosal surfaces to induce mucosal immunity against the antigens displayed on the surface of, or secreted from the htrB mutant. The resultant htrB mutant can be used in a vaccine formulation which expresses the bacterial antigen(s).

Similar methods can be used to construct an inactivated htrB mutant vaccine formulation except that the htrB mutant is inactivated, such as by chemical means known in the art, prior to use as an immunogen and without substantially affecting the immunogenicity of the expressed immunogen(s). For example, human, bronchial mucosal immunity has been stimulated with an aerosol vaccine comprising lysed H. influenzae (Latil et al., 1986, J Clin Microbiol 23:1015–1021). Either of the live htrB mutant vaccine or the inactivated htrB mutant vaccine may also be formulated with a suitable adjuvant in order to further enhance the immunological response to the antigen(s) expressed by the vaccine vector, as to be described in more detail.

In another aspect of this embodiment, the endotoxin is isolated from the htrB mutant using methods known in the art, and the isolated htrB endotoxin is used in a vaccine formulation. As mentioned previously, major antigenic determinants of gram-negative bacteria are believed to reside in the carbohydrate structure of the O-specific side chain of LPS and the complex carbohydrate structure of LOS. However, the chemical nature of LPS and LOS prevent the use of these molecules in vaccine formulations; i.e., active immunization with LPS or LOS is unacceptable due to the inherent toxicity of the secondary acyl chains of the lipid A portion of endotoxin. The endotoxin isolated from an htrB mutant of a gram-negative bacterial pathogen lacks one or more secondary acyl chains, and thus exhibiting substantially reduced toxicity as compared to endotoxin isolated from the respective wild type bacteria. Therefore, endotoxin isolated from an htrB mutant of a gram-negative bacterial pathogen can be used in a vaccine formulation in inducing immunity against the respective wild type gram-negative bacterial pathogen. LPS or LOS can be isolated by the phenol-water method (Westphal et al., 1965, Methods in Carbohydrate Chemistry 5:83–91); or using an alternative purification procedure (using a protease; Hitchcock et al., 1983, J. Bacteriol. 154:269–277).

Many methods are known for the introduction of a vaccine formulation into the human or animal (collectively referred to as “individual”) to be vaccinated. These include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, ocular, intranasal, and oral administration. Conventionally, vaccine formulations containing either live bacteria, or attenuated or inactivated bacteria, are administered by injection or by oral administration. For example, respiratory immunity can be stimulated by intestinal immunization with purified H. influenzae antigens (Cripps et al., 1992, J. Infect Dis 165S1: S199–201; herein incorporated by reference). The vaccine formulation may comprise a physiologically acceptable solution as a carrier in which the htrB bacterial cells or isolated htrB endotoxin is suspended. Various adjuvants may be used in conjunction with vaccine formulations. The adjuvants aid by modulating the immune response and in attaining a more durable and higher level of immunity using smaller amounts of vaccine antigen or fewer doses than if the vaccine antigen were administered alone. Examples of adjuvants include incomplete Freund’s adjuvant, Adjuvant 65 (containing peanut oil, mannide monooleate and aluminum monostearate), oil emulsions, Ribi adjuvant, the Pluronic™ polyols,
polyamines, Avridine, Quil A, saponin, MPL, Q8-21, and mineral gels such as aluminum hydroxide, aluminum phosphate, etc. The vaccine formulation is administered in a prophylactically effective amount to be immunogetic, which depends on factors including the individual’s ability to mount an immune response, the degree of protection to be induced, and the route of administration.

In another aspect of the invention, the vaccine formulation can be administered orally by including it as part of the feed given to economically important livestock. As known by those skilled in the art, species of Haemophilus, Campylobacter, Pseudomonas, and Salmonella are pathogenic for economically important livestock. Using the methods according to the present invention, as illustrated in the following examples, htrB mutants of such animal pathogens can be produced. The resultant htrB mutants, or endotoxin isolated therefrom, can be used in a vaccine formulation. Use of vaccine formulations, containing one or more antigens of various microbial pathogens, in animal feed has been described previously (See for example, Pritchard et al., 1978, Avian Dis. 22:562–575).

**EXAMPLE 5**

**H. influenzae htrB Mutants as Immunogens**

In one embodiment, the htrB mutant is an *H. influenzae* htrB mutant. *Haemophilus influenzae* is an important human respiratory tract pathogen in disease including otitis media, chronic sinusitis, and chronic obstructive pulmonary disease. Certain surface-exposed bacterial components, including P2, P6 and LOS, appear to be antigens which may confer a protective immune response in immunized humans. Such antigens have been shown to be targets of bactericidal antibody, and the presence of serum bactericidal antibody is associated with protection from infection by *H. influenzae* (Faden et al., 1989; J. Infect. Dis. 160:999–1004).

In one embodiment the *H. influenzae* htrB mutant is genetically engineered to express one or more heterologous bacterial antigens. As will be discussed in more detail below, *H. influenzae* has a natural genetic transformation process involving linearized DNA binding, uptake via one or more uptake sequences (e.g. AAGT-GCCGTT—SEQ ID NO:3), translocation, and recombination. Thus, one mechanism to introduce a recombinant DNA molecule containing the at least one heterologous bacterial antigen to be expressed, is to transform the host *H. influenzae* htrB mutant with linearized recombinant DNA molecule containing the DNA encoding the at least one heterologous bacterial antigen (“the encoding sequence”). Alternatively, the recombinant DNA molecule containing the encoding sequence to be expressed can be inserted into a plasmid vector, and either introduced into as a linearized recombinant molecule by the natural transformation process; as circularized recombinant plasmid using electroporation of noncompetent *H. influenzae* htrB mutants; or as a circularized recombinant plasmid transformed into competent *H. influenzae* htrB mutants.

Plasmids useful for cloning of and expression from recombinant DNA molecules in *H. influenzae* are known to those skilled in the art. Such plasmids include: pRSF0885 confers ampicillin resistance, and contains a PvuII cloning site and a defective TnA sequence (Setlow et al., 1981, J. Bacteriol. 148:804–811), and can replicate in both *H. influenzae* and *E. coli* (Trieu et al., 1990, Gene 86:99–102).

pDM2 was constructed by cloning chloramphenicol resistance into pRSF0885; and pDM5 was constructed by cloning tetracycline resistance into pRSF0885 (McCarthy et al., 1986, J. Bacteriol. 168:186–191).

pVT63, pVT64, pVT65, pVT66 are improved shuttle vectors for *H. influenzae* and *E. coli* based on pDM2 (Trieu et al., 1990, Gene 86:99–102), and contain the pUC-derivative of the ColE1 ori, and the pRSF0885 rep locus. Additionally, each plasmid has drug markers with unique restriction sites for insertion into the drug marker as follows: pVT63-ApR (HincII, PstI, Scal), KmR (ClaI, HindIII, NruI, SmaI, XhoI); pVT64-ApR (HincII, PstI, Scal, SspI), SpR; pVT65-ApR (HincII, PstI, Scal, PvuII, SspI), CmR (BglII, NcoI); pVT66-ApR (HincII, PstI, Scal, PvuII), CmR (SmaI).

pACYC177, pACYC184, pSU2718, pSU2719 are improved shuttle vectors for *H. influenzae* and *E. coli* based on pL5A (Chandler, 1991, Plasmid 25:221–224), have the pL5A ori, and are compatible with a plasmid containing the RSF0885 origin of replication. Additionally, each plasmid has multiple cloning sites restriction sites and drug markers as follows: pACYC177-ApR, KmR (Accession No. X06402); pACYC184-CmR, TcR (Accession No. X06403); pSU2718-CmR and polycloning site from pUC18 (Accession No. M64731); and pSU2719-CmR and polycloning site from pUC19 (Accession No. M64732).

pQL1 is an improved shuttle vector for use in *H. influenzae* and *E. coli* containing both the pMB1 ori and pL5a ori, KanR which is flanked by *H. influenzae* uptake sequences, a multiple cloning site containing a unique BamHI and SmaI restriction sites, and which is particularly suited for analyzing *H. influenzae* promoter strength in *H. influenzae* (Heidecker et al., 1994, Gene 150:141–144).

In cloning the recombinant DNA molecule containing the encoding sequence into a plasmid vector, one skilled in the art will appreciate that the choice of restriction enzymes for digesting both the recombinant DNA molecule and the plasmid to result in compatible ends for ligation depends on the unique restriction enzyme sites at the ends of the recombinant DNA molecule, whether occurring naturally or engineered such as during enzymatic amplification; or one or more unique restriction enzyme sites within the plasmid vector, whether insertion into the plasmid vector will assist in the selection process (See, e.g., pVT66); and whether a plasmid-derived promoter is used solely, in addition to the promoter(s) of the encoding sequences, to drive expression from the recombinant DNA molecule. Selection and screening of transformed *H. influenzae* htrB mutants may be accomplished by methods known in the art including detecting the expression of a marker gene (e.g., drug resistance marker) present in the plasmid, and immunodetection of the expressed and displayed heterologous bacterial antigen. While this aspect of the embodiment illustrates that the recombinant DNA molecule containing the encoding sequence can be inserted into a plasmid and expressed in *H. influenzae* htrB mutants, it will be appreciated by those skilled in the art that vectors other than plasmids, can be used including, but not limited to, bacteriophage vectors.

Successful expression of the at least one heterologous bacterial antigen requires that either the recombinant DNA molecule comprising the encoding sequence, or the vector itself, contain the necessary control elements for transcription and translation which is compatible with, and recognized by the particular host system used for expression. Using methods known in the art of molecular biology, including methods described above, various promoters and
enhancers can be incorporated into the vector or the recombinant DNA molecule containing the encoding sequence to increase the expression of the heterologous bacterial antigen, provided that the increased expression of the heterologous bacterial antigen(s) is compatible with (for example, non-toxic to) the htrB mutant. As referred to herein, the encoding sequence can contain DNA encoding more than one heterologous bacterial antigen, and may include viral and/or fungal antigen-encoding sequences, to create a multivalent antigen for use as an improved vaccine composition.

The selection of the promoter will depend on the expression system used. For example, a preferred promoter in an H. influenzae expression system may be the P2 or P6 promoter operatively linked to the encoding sequence. Promoters vary in strength, i.e., ability to facilitate transcription. Generally, for the purpose of expressing a cloned gene, it is desirable to use a strong promoter in order to obtain a high level of transcription of the gene and expression into gene product. For example, bacterial, phage, or plasmid promoters known in the art from which a high level of transcription has been observed in a host cell system comprising E. coli include the lac promoter, trp promoters, recA promoter, ribosomal RNA promoter, the P2 and P6 promoters, lacUV5, ompF, bla, lpp, and the like, may be used to provide transcription of the inserted encoding sequence.

Other control elements for efficient gene transcription or message translation include enhancers, and regulatory signals. Enhancer sequences are DNA elements that appear to increase transcriptional efficiency in a manner relatively independent of their position and orientation with respect to a nearby gene. Thus, depending on the host cell expression vector system used, an enhancer may be placed either upstream or downstream from the encoding sequence to increase transcriptional efficiency. These or other regulatory sites, such as transcription or translation initiation signals, can be used to regulate the expression of the encoding sequence. Such regulatory elements may be inserted into the recombinant DNA molecule containing the encoding sequence, or nearby vector DNA sequences using recombinant DNA methods described herein, and known to those skilled in the art, for insertion of DNA sequences.

Accordingly, a recombinant DNA molecule containing an encoding sequence, can be ligated into an expression vector at a specific site in relation to the vector’s promoter, control, and regulatory elements so that when the recombinant vector is introduced into the htrB mutant, the heterologous bacterial antigen can be expressed in the host cell. The recombinant vector is then introduced into the htrB mutant, and the transformed htrB mutants are selected, and screened for those cells containing the recombinant vector. Selection and screening may be accomplished by methods known in the art, and depending on the vector and expression system used.

The introduction of a recombinant DNA molecule containing the encoding sequence (including an expression vector or plasmid containing the same) into H. influenzae htrB mutants can be accomplished in any one of three processes: a natural genetic transformation process; transformation of competent bacterial cells; and electroporation of non-competent bacterial cells.

Natural Transformation Process

The natural genetic transformation process of H. influenzae involves linearized DNA binding, uptake via one or more uptake sequences, translocation, and recombination. Thus, one mechanism to introduce a recombinant DNA molecule containing the encoding sequence to be expressed into at least one heterologous bacterial antigen, is to transform the host H. influenzae with linearized recombinant DNA molecule containing the encoding sequence; or a linearized vector having inserted into it the recombinant DNA molecule containing the encoding sequence to be expressed. In this natural process, when the linearized DNA is translocated intracellularly, one of the translocated strands of DNA is apparently degraded by exonuclease activity (Barnay et al., 1983, Proc. Natl. Acad. Sci. USA 80:7274–7278). If the translocated strand lacks homology sufficient for recombination into the H. influenzae chromosome, the translocated strand becomes susceptible to further degradation (Pifer et al., 1985, Proc. Natl. Acad. Sci. USA 82:3731–3735). Using methods known in the art (e.g., Barnay et al., 1983, supra; herein incorporated by reference), linearized DNA containing the encoding sequence can be introduced into H. influenzae htrB mutants. Since the encoding sequence can be flanked by H. influenzae sequences, to increase the likelihood of recombination of the encoding sequence into the H. influenzae htrB mutants’ genome is likely to occur.

Transformation of Competent Bacterial Cells

Another mechanism to introduce a recombinant DNA molecule containing the encoding sequence to be expressed into at least one heterologous bacterial antigen, is to transform competent host H. influenzae htrB mutants with a circular vector, such as a plasmid, having inserted into it the recombinant DNA molecule containing the encoding sequence to be expressed. Competence of H. influenzae develops best under conditions in which the bacterial cell duplication is inhibited, such as a temporary shift to anaerobic conditions, by physiological change occurring during late-log phase growth, and transfer of cells into nutrient-poor, chemically-defined medium. Such defined media for the development of competence of H. influenzae has been previously described in detail (Herriott et al., 1970, J. Bacteriol. 101:517–524; herein incorporated by reference). It appears that only a short time after entering competent H. influenzae, a plasmid containing sequences homologous to the bacterial chromosome can insert its homologous sequence (such as the encoding sequence flanked by H. influenzae sequences) into the chromosome via recombination (Setlow et al., 1981, supra) for expression. Thus, in this embodiment, a plasmid containing the encoding sequence which is capable of being transformed into competent H. influenzae htrB mutants is introduced by methods for transformation known in the art (Kuniladuparum et al., 1995, J. Bacteriol. 177:3235–3240; Setlow et al., 1981, supra, herein incorporated by reference). The encoding sequence may then be recombined into the H. influenzae htrB mutants’ genome where it is expressed under the control of its own promoter or an H. influenzae promoter near the site of insertion. Such transformation is reported to be at a relatively high frequency (McCarthy and Cox, 1986, J. Bacteriol., 168:186–191).

Alternatively, transformation of competent H. influenzae htrB mutants by a circular plasmid with the appropriate origin(s) of replication and containing the encoding sequence may result in plasmid establishment; i.e., a plasmid coexisting as an extrachromosomal element without recombination. Examples of such plasmids have been described above. Thus, in this variation of the embodiment, a plasmid containing the encoding sequence which is capable of being transformed into, and established in, competent H. influenzae htrB mutants is introduced by methods for transformation known in the art. The encoding sequence
is then expressed from the plasmid under the control of its own promoter or a promoter within the vector.

Electroporation of Non-Competent Bacterial Cells

Yet another mechanism to introduce a recombinant DNA molecule containing the encoding sequence to be expressed into at least one heterologous bacterial antigens, is to introduce a circular vector, such as a plasmid having inserted into it the recombinant DNA molecule containing the encoding sequence to be expressed, into non-competent host *H. influenzae* htrB mutants by electroporation. Electroporation has been used to efficiently introduce plasmid DNA into bacteria. However, optimal conditions may differ depending on the host cell used. Optimal conditions have been described for electroporating plasmid DNA into *H. influenzae* (Mitchell et al., 1991, *Nucl. Acids Res*. 19:3625–3628; herein incorporated by reference). It was found that electroporation of plasmid into *H. influenzae* made competent by defined, nutrient poor media was several orders of magnitude less efficient than electroporation into non-competent *H. influenzae*. Thus, in this variation of the embodiment, it would be preferred that a plasmid containing the encoding sequence is electroporated into non-competent *H. influenzae* htrB mutants. The plasmid is capable of being established in *H. influenzae* htrB mutants, or is degraded after the encoding sequence has recombined into the *H. influenzae* htrB mutants’ genome. In either case, the encoding sequence is under the control of its own promoter, or a promoter within the vector or genome, respectively.

**EXAMPLE 6**

**Neisserial htrB Mutants as Immunogens**

In another embodiment, the htrB mutant is a Neisserial htrB mutant selected from the group including *Neisseria gonorrhoeae*, and *Neisseria meningitidis*. *N. gonorrhoeae* is a gram-negative bacterial pathogen causing the sexually transmitted disease gonorrhea, which subsequently can lead to pelvic inflammatory disease in females. *N. meningitidis* is a gram-negative bacterial pathogen which can cause a variety of clinical infections including bacteremia, septicaemia, meningitis, and pneumonia. Alterations in the terminal glycosylation of the LOS of *Neisseria* are believed correlate with serum sensitivity and serum resistance of the organism. Further, protective bactericidal antibody is directed against type-specific antigens of *N. meningitidis*, wherein the type-specific antigens have been identified as outer membrane proteins, or LOS, or both.

Using the methods according to the present invention, as illustrated in Examples 1–3, htrB mutants of a Neisserial species can be produced and identified. One skilled in the art, using the htrB gene of *H. influenzae*, can isolate the htrB gene of the Neisserial species, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in a Neisserial htrB mutant lacking one or more secondary acyl chains. Alternatively, there may be sufficient homology between *Neisseria and Haemophilus* to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform *Neisseria* species for recombination of the mutant htrB gene into the htrB gene. Haemophilius transformants are then selected for by growth in the presence of chloramphenicol (1.5 μg/ml), resulting in identification of Haemophilus htrB mutant strains. Locations of the mini-Tn3 insertions in the chromosomes of Haemophilus htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant Neisserial htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, Neisserial htrB mutants can be used in a live bacterial vaccine preparation, in an inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into Neisserial species are known to those skilled in the art, including: pL823 confers ampicillin resistance, is a shuttle vector functional in both *E. coli* and *N. gonorrhoeae*, and contains a polylinker with restriction sites for EcoRI, SmaI, and BamHI (Stein et al., 1983, *Gene* 25:241–247).

**Neisserial species also contain a natural transformation process** (Rudel et al., 1995, *Proc Natl Acad Sci USA* 92:7886–90; Goodman et al., 1991, *J Bacteriol* 173:5921–5923); and can also be made competent or be electroporated using techniques known to those skilled in the art.

**EXAMPLE 7**

**Haemophilus ducreyi htrB Mutants as Immunogens**

In another embodiment, the mutant is a *H. ducreyi* htrB mutant. *H. ducreyi* is a gram-negative bacterial pathogen causing a genital ulcer disease, chancroid. Using the methods according to the present invention, as illustrated in Examples 1–3, *H. ducreyi* htrB mutants can be produced and identified. One skilled in the art, using the htrB gene of *H. ducreyi*, can isolate the htrB gene of *H. ducreyi*, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in an *H. ducreyi* htrB mutant lacking one or more secondary acyl chains. Alternatively, there is likely sufficient homology between *H. ducreyi* and *H. influenzae* to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform *H. ducreyi* for recombination of the mutant htrB gene into the *H. ducreyi* htrB gene. Haemophilius transformants are then selected for by growth in the presence of chloramphenicol (1.5 μg/ml), resulting in identification of *H. ducreyi* htrB mutant strains. Locations of the mini-Tn3 insertion in the chromosomes of the *H. ducreyi* htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant *H. ducreyi* htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, *H. ducreyi* htrB mutants can be used in a live bacterial vaccine preparation, in an inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into *Haemophilus* species are known to those skilled in the art, as disclosed in
EXAMPLE 8

Campylobacter jejuni htrB Mutants as Immunogens

In another embodiment, the mutant is a C. jejuni htrB mutant. Campylobacter jejuni is a gram-negative bacterial pathogen causing human enteritis. Infection by C. jejuni has also been associated with the onset of neurologic disorders such as Guillain-Barré syndrome. C. jejuni htrB mutants can be produced and identified. One skilled in the art, using the htrB gene of H. influenzae, can isolate the htrB gene of C. jejuni, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in an C. jejuni htrB mutant lacking one or more secondary acyl chains. Alternatively, there may be sufficient homology between C. jejuni and H. influenzae to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform M. catarrhalis for recombination of the mutant htrB gene into the M. catarrhalis htrB gene. M. catarrhalis transformants are then selected for by growth in the presence of chloramphenicol (1.5 μg/ml), resulting in identification of M. catarrhalis htrB mutant strains. Locations of the mTn3 insertion in the chromosomes of the M. catarrhalis htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant M. catarrhalis htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, M. catarrhalis htrB mutants can be used in a live bacterial vaccine preparation, in an inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into C. jejuni are known to those skilled in the art, and includes:

pUA466 confers tetracycline resistance, and contains an unique Avai site and Avai site (Taylor, 1986, J Bacteriol 165:1037–39). C. jejuni can also be made competent or be electroporated using techniques known to those skilled in the art.

EXAMPLE 9

Moraxella catarrhalis htrB Mutants as Immunogens

In another embodiment, the mutant is a M. catarrhalis htrB mutant. Moraxella catarrhalis is a gram-negative bacterial pathogen causing otitis media in children; sinusitis and conjunctivitis in children and adults; and lower respiratory tract infections, septicemia, and meningitis in immunocompromised hosts. M. catarrhalis htrB mutants can be produced and identified. One skilled in the art, using the htrB gene of H. influenzae, can isolate the htrB gene of M. catarrhalis, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in an M. catarrhalis htrB mutant lacking one or more secondary acyl chains. Alternatively, there may be sufficient homology between M. catarrhalis and H. influenzae to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform M. catarrhalis for recombination of the mutant htrB gene into the M. catarrhalis htrB gene. M. catarrhalis transformants are then selected for by growth in the presence of chloramphenicol (1.5 μg/ml), resulting in identification of M. catarrhalis htrB mutant strains. Locations of the mTn3 insertion in the chromosomes of the M. catarrhalis htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant M. catarrhalis htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, M. catarrhalis htrB mutants can be used in a live bacterial vaccine preparation, in an inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into M. catarrhalis are known to those skilled in the art.

M. catarrhalis contains a natural transformation process (Juni, 1977, J Clin Microbiol 5:227–35) and can also be made competent or be electroporated using techniques known to those skilled in the art.

EXAMPLE 10

Salmonella htrB Mutants as Immunogens

In another embodiment, the mutant is a Salmonella htrB mutant. Salmonella species comprise gram-negative bacteria that can cause a variety of clinical illnesses in humans and animals. For example, S. typhi is the causative agent of typhoid fever in humans. S. paratyphi is a causative organism of a fever known as salmonella fever in humans. Salmonellosis, a gastroenteritis in humans, can be caused by various species in the genus Salmonella (typhimurium, newport, heidelberg, and enteritidis). Salmonella htrB mutants can be produced and identified. One skilled in the art, using the htrB gene of H. influenzae, can isolate the htrB gene of Salmonella species, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in a Salmonella htrB mutant lacking one or more secondary acyl chains. Alternatively, there may be sufficient homology between Salmonella and H. influenzae to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform Salmonella for recombination of the mutant htrB gene into the Salmonella htrB gene. Salmonella transformants are then selected for by growth in the presence of chloramphenicol (1.5 μg/ml), resulting in identification of Salmonella htrB mutant strains. Locations of the mTn3 insertion in the chromosomes of the Salmonella htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant Salmonella htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.
reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, Salmonella htrB mutants can be used in a live bacterial vaccine preparation, in an inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into Salmonella are known to those skilled in the art, and includes:


pBl7 confers kanamycin and chloramphenicol resistance, and contains a cloning site flanked by a Ball site and a HindIII site (Purcell et al., 1983, Infect Immun 39:1122-1127).

pACK5 contains the replicon of pAC1 from Acetobacter pasteurianus and confers kanamycin resistance (Grones et al., 1995, Biochim Biophys Res Commun 206:942-947).

pVAC468 is a suicide vector for chromosomal insertion of heterologous antigens into Salmonella and contains a polylinker having the following restriction sites: CiaI, EcoRV, XhoI, SacI, Sall, Smal, XbaI, and BglII (Hohmann et al., 1995, Proc Natl Acad Sci USA 92:2904-2908).

Also disclosed is a bacteriophage system, a chromosomal expression vector for inserting genes encoding foreign antigens into the chromosome of Salmonella, which uses a defective transposable element carried on bacteriophage lambda (Flynn et al., 1990, Mol. Microb 4:2111-2118).

Salmonella can also be made competent (see for example, Purcell et al., 1983, supra) or be electroporated using techniques known to those skilled in the art (see for example, Grones et al., 1995, supra; Coulson et al., 1994, supra).

EXAMPLE 11

Shigella htrB Mutants as Immunogens

In another embodiment, the mutant is a Shigella species htrB mutant. Members of the genus Shigella are gram-negative bacteria which cause diseases such as dysentery (pathogenic species include sonnei, and flexneri) primarily in humans. Shigella htrB mutants can be produced and identified. One skilled in the art, using the htrB gene of H. influenzae, can isolate the htrB gene of Pseudomonas aeruginosa, and produce a mutated htrB gene (unable to encode functional HtrB) using transposon mutagenesis with subsequent recombination resulting in an Shigella htrB mutant lacking one or more secondary acyl chains. Alternatively, there may be sufficient homology between Shigella and H. influenzae to use plasmids pB28 and pB29, each with a mini-Tn3 transposon containing the chloramphenicol acetyltransferase (CAT) gene inserted into the htrB open reading frame at a different location, to transform P. aeruginosa for recombination of the mutant htrB gene into the P. aeruginosa htrB gene. P. aeruginosa transformants are then selected for by growth in the presence of chloramphenicol (1.5 µg/ml), resulting in identification of P. aeruginosa htrB mutant strains. Locations of the mini-Tn3 insertion in the chromosomess of the P. aeruginosa htrB mutants may be confirmed by genomic Southern hybridization using a probe containing htrB sequences. The resultant P. aeruginosa htrB mutants can then be tested for substantially reduced toxicity using assays described by those skilled in the art for measuring the toxic effects induced by endotoxin.

Using the methods according to the present invention, as illustrated in Examples 4 & 5, P. aeruginosa htrB mutants can be used in a live bacterial vaccine preparation, in an
inactivated bacterial vaccine preparation, and can be genetically engineered to express at least one heterologous bacterial antigen in a multivalent vaccine preparation. Regarding the latter aspect, plasmids useful for cloning of and expression from recombinant DNA molecules into P. aeruginosa are known to those skilled in the art, and includes:


P. aeruginosa can also be made competent (see for example, Hoyne et al., 1992, supra) or be electroporated using techniques known to those skilled in the art.

EXAMPLE 12

Multivalent htrB Mutant Vaccine Formulation

In one embodiment according to the present invention, as illustrated in Examples 4 & 5, the htrB mutant is genetically engineered to express one or more heterologous microbial antigens in producing a multivalent vaccine using methods known to those skilled in the art. In a preferred embodiment, a microbial pathogen may include a respiratory pathogen selected from the group of pathogens, with respective antigens, in Table 1.

<table>
<thead>
<tr>
<th>PATHOGEN</th>
<th>INFECTION/DISEASE</th>
<th>PROTEIN ANTIGEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. influenzae</td>
<td>otitis media, lower respiratory tract</td>
<td>D-15, P1, P6</td>
</tr>
<tr>
<td>Group A</td>
<td>pneumonia, rheumatic fever</td>
<td>M2</td>
</tr>
<tr>
<td>Streptococcus</td>
<td>pneumococcus, otitis media, lower respiratory tract</td>
<td>CD, E2</td>
</tr>
<tr>
<td>Branhamella catarrhalis</td>
<td>pertussis (whooping cough)</td>
<td>autolysin, pneumolysin</td>
</tr>
<tr>
<td>Bordetella pertussis</td>
<td>pertussis (whooping cough)</td>
<td>filamentous hemagglutinin, pertussis toxin</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>respiratory tract</td>
<td>Omp OmpF, exotoxin</td>
</tr>
<tr>
<td>Legionella pneumophila</td>
<td>pneumonia</td>
<td>OmpS, Hsp60</td>
</tr>
<tr>
<td>Mycoplasma pneumoniae</td>
<td>upper and lower respiratory tract</td>
<td>P18</td>
</tr>
<tr>
<td>Respiratory syncytial virus</td>
<td>lower respiratory tract</td>
<td>M2, F, G</td>
</tr>
<tr>
<td>Influenza virus</td>
<td>influenza</td>
<td>HA, M</td>
</tr>
<tr>
<td>Adenosinovirus</td>
<td>common cold</td>
<td>VP1, VP2, VP3</td>
</tr>
<tr>
<td>Rhesovirus</td>
<td>common cold</td>
<td>HN</td>
</tr>
<tr>
<td>Pneumocystis carinii</td>
<td>pneumonia in AIDS</td>
<td>msg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PATHOGEN</th>
<th>INFECTION/DISEASE</th>
<th>PROTEIN ANTIGEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. gonorrhoeae</td>
<td>gonorrhea</td>
<td>IgA1 protease</td>
</tr>
<tr>
<td>Chlamydia trachomatis</td>
<td>mongonacoccal</td>
<td>MOMP</td>
</tr>
<tr>
<td>Ureaplasma urethritis</td>
<td>urethritis</td>
<td>IISP</td>
</tr>
</tbody>
</table>

In another preferred embodiment, a microbial pathogen may include a pathogen causing a sexually transmitted disease selected from the group of pathogens, with respective antigens, in Table 2.

<table>
<thead>
<tr>
<th>PATHOGEN</th>
<th>INFECTION/DISEASE</th>
<th>PROTEIN ANTIGEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. gonorrhoeae</td>
<td>gonorrhea</td>
<td>IgA1 protease</td>
</tr>
<tr>
<td>Chlamydia trachomatis</td>
<td>mongonacoccal</td>
<td>MOMP</td>
</tr>
<tr>
<td>Ureaplasma urethritis</td>
<td>urethritis</td>
<td>IISP</td>
</tr>
</tbody>
</table>

Tables 1 & 2, and the references footnoted which are herein incorporated by reference, illustrate various protein antigens, or peptides thereof, viewed by those skilled in the art to be useful as vaccine candidates against the respective microbial pathogen. Typically, the immunopotentency of an epitope, whether from a protein or peptide, of a microbial pathogen is determined by monitoring the immune response of an animal following immunization with the epitope and/or by analyzing human convalescent sera in conjunction with pre-immune sera. Thus, one skilled in the art can determine protein or peptide antigens from microbial pathogens which would be desired to include as a heterologous antigen to be expressed by an htrB mutant according to the present invention. A corresponding nucleic acid sequence, the encoding sequence, can then be deduced from the amino acid sequence of the protein or peptide antigen, wherein the encoding sequence is introduced into the htrB mutant for expression.

EXAMPLE 13

Use of htrB Mutants to Generate Antisera

The htrB mutant, or endotoxin purified therefrom, can be used to generate endotoxin-specific antisera, directed to the particular gram-negative bacterial pathogen, which can be used in an immunosay to detect the antigen (that particular gram-negative bacterial pathogen), present in the body fluid of an individual suspected of having an infection caused by that gram-negative bacterial pathogen. The body fluid(s) collected for analysis depend on the microorganism to be detected, the suspected site of infection, and whether the body fluid is suspected of containing the antigen or containing antisera. With those considerations in mind, the body fluid could include one or more of sputum, blood, cerebrospinal fluid, lesion exudate, swabbed material from the suspected infection site, and fluids from the upper respir-
The activity tract. Immunoassays for such detection comprises any immunoassay known in the art including, but not limited to, radioimmunoassay, ELISA, "sandwich" assay, precipitin reaction, agglutination assay, fluorescent immunoassay, and chemiluminescence-based immunoassay.

Alternatively, where an immunocompromised individual is suffering from a potentially life-threatening infection caused by a particular gram-negative bacterial pathogen, immunization may be passive, i.e. immunization comprising administration of purified human immunoglobulin containing antibody against an htrB mutant or isolated htrB endotoxin of that particular gram-negative bacterial pathogen.

It should be understood that while the invention has been described in detail herein, the examples were for illustrative purposes only. Other modifications of the embodiments of the present invention that are obvious to those skilled in the art of molecular biology, medical diagnostics, and related disciplines are intended to be within the scope of the appended claims.

**SEQUENCE LISTING**

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 3

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 969 nucleotides
(B) TYPE: nucleic acid
(C) STRANDINESS: double-stranded
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: genomic DNA

(iii) HYPOTHETICAL: yes

(vi) ORIGINAL SOURCE:
(A) ORGANISM: H. influenzae
(B) STRAIN: 2019
(G) CELL TYPE: bacterium

(xii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

<table>
<thead>
<tr>
<th>TAAACATGCC CCTCAATTTA CTTTTAGAAGA ACA ATG AAA AAC GAA AAA CTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>51 Met Lys Aen Glu Lys Leu 1 5</td>
</tr>
<tr>
<td>CCT CAA TTT CAA CCGCAC TTT TTA GCC CCA AAA TAC TGG CTT TTT</td>
</tr>
<tr>
<td>Pro Gln Phe Gln Pro His Phe Leu Ala Pro Lys Tyr Trp Leu Phe</td>
</tr>
<tr>
<td>10 15 20</td>
</tr>
<tr>
<td>TGG CTA GCC GTG GCA ATT TGG CCA AGT ATT TTA TGT CCT CCC TAT</td>
</tr>
<tr>
<td>Trp Leu Gly Val Ala Trp Arg Ser Ile Leu Cys Leu Pro Tyr</td>
</tr>
<tr>
<td>25 30 35</td>
</tr>
<tr>
<td>CCT ATT TGC CCC CAT ATT GGT CAT GTC GTC CGT CGT TTT CTT CCA</td>
</tr>
<tr>
<td>Pro Ile Leu Arg His Ile Gly His Gly Phe Gly Tryp Leu Phe Ser</td>
</tr>
<tr>
<td>40 45 50</td>
</tr>
<tr>
<td>CAT TTA AAA GCT GGT AAA CTT CCA GCC ATT GCA GCC AAT CAT</td>
</tr>
<tr>
<td>His Leu Lys Val Gly Lys Arg Arg Ala Ala Ile Arg Aas</td>
</tr>
<tr>
<td>55 60 65</td>
</tr>
<tr>
<td>CTT GAA CTT GTT TTC CCT GAT ATG CTT GCA AAC GAA COT GAC GCG</td>
</tr>
<tr>
<td>Leu Glu Leu Cys Phe Pro Asp Met Pro Glu Aan Glu Arg Glu Thr</td>
</tr>
<tr>
<td>70 75 80</td>
</tr>
<tr>
<td>ATT TGG CAA GAA AAT CTT CCT TCA GTA GCC ATG GCA ATT ATC GAA</td>
</tr>
<tr>
<td>Ile Leu Glu Aen Leu Arg Ser Val Gly Met Ala Ile Ile Glu</td>
</tr>
<tr>
<td>85 90 95</td>
</tr>
<tr>
<td>ACT GCC ATG CTT TGG TTT TTG TGG GAT TCA GCT ATC AAA AAA TGG</td>
</tr>
<tr>
<td>Thr Gly Met Ala Trp Phe Trp Ser Asp Ser Arg Ile Lys Lye Trp</td>
</tr>
<tr>
<td>100 105 110</td>
</tr>
<tr>
<td>TGG AAA GRT GAA GCC TTA CAT TAT CTA AAA GAA AAT CAA AAA CAT</td>
</tr>
<tr>
<td>Ser Lys Val Glu Gly Leu His Tyr Leu Lys Glu Aan Lys Aep</td>
</tr>
<tr>
<td>115 120 125</td>
</tr>
<tr>
<td>GGA ATT GTT CTC GTC GCC GTT CAT TTC TTA ACG CTA GAA CTT GCC</td>
</tr>
<tr>
<td>Gly Ile Val Leu Val Val His Phe Leu Thr Leu Glu Leu Gly</td>
</tr>
<tr>
<td>456</td>
</tr>
</tbody>
</table>
GCA GCC ATC ATT GGT TTA CAT CAT CCT GCC ATT GGT GTT TAT COT
Ala Arg Ile Ile Gly Leu His His Pro Gly Ile Gly Val Tyr Arg
145 150 155

CCA AAT GAT GAA CCT TGG CTT GAT TGG CTA CAA ACA GCC CGT
Pro Asp Asn Asn Pro Leu Pro Asp Trp Leu Glu Thr Glu Gly Arg
160 165 170

TTA GCC TCC AAT AAA GAT ATG CTT GAT CGT AAA GAT TTA GCC GGA
Leu Arg Ser Asn Lys Asp Met Leu Asp Arg Lys Asp Leu Arg Gly
175 180 185

ATG ATC AAA GCT TTA GCC CAC GAA GAA ACC ATT TGG TAT GCG CCT
Met Ile Lys Ala Leu Arg His Glu Glu Thr Ile Trp Tyr Ala Pro
190 195 200

GAT CAC GAT TAC GCC AGA AAA AAT GCC GAT TTT GTT CCT TTT TTT
Asp His Asp Tyr Arg Lys Asn Asp Val Phe Pro Phe Phe
205 210 215

GCA GTA CCT GAC ACT TGC ACT ACT ACT GGT AGT TAT TAT TTA TTG
Ala Val Pro Asp Thr Cys Thr Thr Gly Ser Tyr Tyr Leu Leu
220 225 230

AAA TCC TCG CAA AAC AGC AAA GAT ATT CCA TTT GCC CCA TTA GCC
Lys Ser Ser Gln Asn Ser Lys Val Ile Pro Phe Pro Leu Arg
235 240 245

AAT AAA GAT GCT TCA GCC TAT ACC GTF AGC ATT TCA GCC CCT GTT
Aaa Lys Asp Gly Ser Gly Tyr Thr Val Ser Ser Ala Asp Val
250 255 260

GAT TTT ACA GAT TTA GAA GTA GCC ATA CCT GTG CAA ATG
Asp Phe Thr Asp Leu Glu Asp Glu Val Ala Ile Ala Ala Arg Met
265 270 275

AAT CAA ATC GCT GAA AAG ACA ATC AGG GCC ATA TCA CAA TAT
Aee Gin Ile Val Glu Lys Glu Ile Met Lys Gly Ile Ser Glu Tyr
280 285 290

ARG TGG CTA GAT GCT CTT TTT AAA ACA GCC CCC GAT GAA AAT ACG
Met Trp Leu His Arg Arg Phe Lys Thr Arg Pro Asp Glu Asn Thr
295 300 305

CCT AGT TTA TAC GAT TAA
Pro Ser Leu Tyr Asp
310

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single-stranded
(D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:
(A) ORGANISM: H. influenzae
(B) STRAIN: 2019

(vii) IMMEDIATE SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCAAATGCCC GCAAAATGGG ATAGGGAGA C

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 nucleotides
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single-stranded
(D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:
What is claimed is:

1. A vaccine formulation comprising an active ingredient, wherein the active ingredient is
   (a) a non-typeable Hemophilus influenzae strain having a mutation in hrB gene, wherein the hrB mutation
   produces a mutant non-typeable Hemophilus influenzae having a mutant endotoxin containing a decreased
   phosphoethanolamine content and an increased hexose content in the mutant endotoxin’s inner core, and a
   pentaacylated or tetraacylated lipid A lacking one or two secondary acyl chains compared to the correspond-
   ing wild-type non-typeable Hemophilus influenzae hexaacylated endotoxin, and wherein the mutant endoto-
  oxin has substantially reduced toxicity as compared to the hexaacylated endotoxin of the wild-type non-type-
   able Hemophilus influenzae, or
   (b) a non-typeable Hemophilus influenzae strain having a mutation in hrB gene, wherein the hrB mutation
   produces a mutant non-typeable Hemophilus influenzae having a mutant endotoxin containing a decreased
   phosphoethanolamine content and an increased hexose content in the mutant endotoxin’s inner core, and a
   pentaacylated or tetraacylated lipid A lacking one or two secondary acyl chains compared to the correspond-
   ing wild-type non-typeable Hemophilus influenzae hexaacylated endotoxin, and wherein the mutant endoto-
   oxin has substantially reduced toxicity as compared to the hexaacylated endotoxin of the wild-type non-type-
   able Hemophilus influenzae.

2. The vaccine formulation according to claim 1, further comprising a physiological carrier and an adjuvant.

3. The vaccine formulation according to claim 1, wherein the active ingredient consists essentially of the non-typeable
   Hemophilus influenzae strain having said mutation in the hrB gene, wherein the hrB mutation produces the mutant
   non-typeable Hemophilus influenzae having the mutant endotoxin containing a decreased phosphoethanolamine
   content and an increased hexose content in the mutant endotoxin’s inner core, and a pentaacylated or tetraacylated
   lipid A lacking one or two secondary acyl chains compared to the corresponding wild-type non-typeable Hemophilus
   influenzae hexaacylated endotoxin, and wherein the mutant endotoxin has substantially reduced toxicity as compared
   to the hexaacylated endotoxin of the wild-type non-typeable Hemophilus influenzae.

4. The vaccine formulation according to claim 1, wherein the active ingredient consists essentially of the non-typeable
   Hemophilus influenzae strain having said mutation in the hrB gene, wherein the hrB mutation produces the mutant
   non-typeable Hemophilus influenzae having the mutant endotoxin containing a decreased phosphoethanolamine
   content and an increased hexose content in the mutant endotoxin’s inner core, and a pentaacylated or tetraacylated
   lipid A lacking one or two secondary acyl chains compared to the corresponding wild-type non-typeable Hemophilus
   influenzae hexaacylated endotoxin, and wherein the mutant endotoxin has substantially reduced toxicity as compared
   to the hexaacylated endotoxin of the wild-type non-typeable Hemophilus influenzae, wherein the hrB mutant non-
   typeable Hemophilus influenzae has been genetically engineered to express at least one heterologous antigen from
   said microbial pathogen.

* * * * *
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 27, line 17, in Claim 1, italicize “htrB” both times it appears.

In column 27, line 30, in Claim 1, italicize “htrB” both times it appears.

In column 27, line 41, in Claim 1, italicize “htrB”.

In column 28, line 16, in Claim 3, italicize “htrB” both times it appears.

In column 28, line 30, in Claim 4, italicize “htrB” both times it appears.

In column 28, line 40, in Claim 4, italicize “htrB”.

Signed and Sealed this

Sixteenth Day of October, 2007

JON W. DUDAS
Director of the United States Patent and Trademark Office